Literature DB >> 3101549

Respiratory interactions of ketamine and morphine.

D L Bourke, L A Malit, T C Smith.   

Abstract

Six healthy, consenting volunteer males received ketamine iv in five logarithmically scaled doses totaling 3 mg/kg on three occasions each. The sessions differed only in the initial injection of an unknown drug: placebo, morphine sulfate 0.2 mg/kg, or morphine sulfate 0.4 mg/kg. Initial and terminal steady-state ventilatory responses to CO2 (VERCO2) and isohypercapnic ventilation (end-tidal CO2 49.8 +/- 2.4 mmHg) during drug administration assessed CO2-mediated ventilatory drive. Oxygen concentration of 40% ablated hypoxic drive contribution. Morphine caused a decrease of isohypercapnic ventilation (VE) of 8.2 +/- 1.2 l/min after 0.2 mg/kg. Doubling the dose to 0.4 mg/kg gave a further depression of 6.6 +/- 1.8 l/min. No subject lost consciouness after morphine. Over a dose range of 0.39 to 3.0 mg/kg ketamine caused log-linear dose-related depression of 1.6 +/- 0.3 l/min for each doubling of dose, although the first significant depression of 4.9 +/- 1.1 l/min did not occur until the third dose (1.1 mg/kg) in the absence of morphine. All subjects were unconscious after 1.8 mg/kg ketamine. Slopes of the VERCO2 did not differ from control, regardless of the pretreatment, placebo, or morphine in the two doses. Ketamine alone, 3.0 mg/kg, caused a displacement of VERCO2 of +2.0 +/- 1.2 mmHg in CO2, while combination of ketamine and morphine in either dose caused a +10 mmHg displacement of VERCO2. Thus, ketamine appears qualitatively similar but less potent than premedicant doses of morphine in depressing respiration despite near equipotency in producing loss of consciousness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101549     DOI: 10.1097/00000542-198702000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  17 in total

Review 1.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

Review 2.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

3.  Prolonged central apnoea after intravenous morphine administration in a 12-year-old male with a UGT1A1 loss-of-function polymorphism.

Authors:  Michael S Toce; Hyun Kim; Sarita Chung; Baruch S Krauss
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

Review 4.  Ketamine: review of its pharmacology and its use in pediatric anesthesia.

Authors:  S A Bergman
Journal:  Anesth Prog       Date:  1999

5.  Isoflurane, ketamine-xylazine, and urethane markedly alter breathing even at subtherapeutic doses.

Authors:  Cory A Massey; George B Richerson
Journal:  J Neurophysiol       Date:  2017-07-26       Impact factor: 2.714

6.  The steady-state and rebreathing methods compared during morphine administration in humans.

Authors:  D L Bourke; A Warley
Journal:  J Physiol       Date:  1989-12       Impact factor: 5.182

7.  Comparison of morphine and morphine with ketamine for postoperative analgesia.

Authors:  K B Javery; T W Ussery; H G Steger; G W Colclough
Journal:  Can J Anaesth       Date:  1996-03       Impact factor: 5.063

8.  Anaesthetic experience with paediatric interventional cardiology.

Authors:  S Malviya; F A Burrows; A E Johnston; L N Benson
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 9.  Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia.

Authors:  D A Haas; D G Harper
Journal:  Anesth Prog       Date:  1992

10.  Pediatric fractures: temporal trends and cost implications of treatment under general anesthesia.

Authors:  A Gulati; A Dixit; G J Taylor
Journal:  Eur J Trauma Emerg Surg       Date:  2011-07-08       Impact factor: 3.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.